AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22364892
Drug: placebo (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (saline injection)
Trial: 19581770
Drug: Clevudine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clevudine therapy
Trial: 17975845
Drug: Extracorporeal albumin
RxNorm normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extracorporeal albumin dialysis (ECAD) + standard medical therapy (SMT)
Trial: 16358599
Drug: No topical
RxNorm normalized name: Altreno Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No topical anesthetic
Trial: 12473473
Drug: Intranasal mupirocin
RxNorm normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal mupirocin ointment for 5 days
Trial: 10496153
Drug: Cefpodoxime proxetil
RxNorm normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefpodoxime proxetil suspension (10mg/kg/day)
Trial: 10496153
Drug: Cefaclor suspension
RxNorm normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefaclor suspension (45mg/kg/day)
Trial: 2696009
Drug: Dexamethasone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (4 mg before or after the operation or 8 mg after the operation)
Trial: 2696009
Drug: 6-methylprednisolone (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-methylprednisolone (16 mg at the end of the operation)
Trial: 326596
Drug: Mazindol therapy
RxNorm normalized name: Mazindol
DrugBank: Mazindol (DB00579)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mazindol therapy
Trial: 28885054
Drug: Zephyr endobronchial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zephyr endobronchial valve (EBV) treatment
Trial: 25204361
Drug: Topical minoxidil
RxNorm normalized name: MINOXIDIL 50 mg in 1 mL TOPICAL SOLUTION [Stafenit Hair Regrowth Treatment Topical Minoxidil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical minoxidil foam 5% (MTF)
Trial: 23144466
Drug: DHEA (LiveWell,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA (LiveWell, 25 mg three times a day)
Trial: 19394002
Drug: Acupuncture (according
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture (according to traditional Chinese medicine principles)
Trial: 17062435
Drug: High-dose omega-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose omega-3 (4.55 g omega-3/day)
Trial: 17062435
Drug: Low-dose omega-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose omega-3 (1.95 g omega-3/day)
Trial: 10965421
Drug: Tramadol hydrochloride
RxNorm normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tramadol hydrochloride injection (Limadol), 100 mg
Trial: 10965421
Drug: Commercially available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercially available reference product, 100 mg
Trial: 1352908
Drug: Ebrotidine (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ebrotidine (800 mg single oral dose)
Trial: 1352908
Drug: Ebrotidine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ebrotidine (3 days treatment)
Trial: 1352908
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 days treatment)
Trial: 6241188
Drug: 13-cis-retinoic acid
RxNorm normalized name: 13-cis-retinoic acid
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 13-cis-retinoic acid (0.05 mg/kg)
Trial: 6241188
Drug: 13-cis-retinoic acid
RxNorm normalized name: 13-cis-retinoic acid
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 13-cis-retinoic acid (0.1 mg/kg)
Trial: 6241188
Drug: 13-cis-retinoic acid
RxNorm normalized name: 13-cis-retinoic acid
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 13-cis-retinoic acid (0.2 mg/kg)
Trial: 6241188
Drug: 13-cis-retinoic acid
RxNorm normalized name: 13-cis-retinoic acid
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 13-cis-retinoic acid (all doses)
Trial: 29202566
Drug: Spray-Sol group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spray-Sol group (18 patients) with HA nebulized using a new nasal device named Spray-Sol
Trial: 29202566
Drug: Spray group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spray group (15 patients) with HA nebulized with a common spray
Trial: 29202566
Drug: Spray-Sol group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spray-Sol group (18 patients)
Trial: 25027139
Drug: Telecare management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telecare management (n=124) for 12 months with automated symptom monitoring and algorithm-guided stepped care approach to optimizing analgesics
Trial: 22470117
Drug: INH-resistant cases
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INH-resistant cases during the continuation phase of treatment (after 3 months)
Trial: 22470117
Drug: Drug-susceptible cases
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-susceptible cases infected with 'modern' Beijing lineage strains
Trial: 11991558
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone propionate (FP) 88 microg twice daily
Trial: 11991558
Drug: Oral zafirlukast
RxNorm normalized name: Zafirlukast
DrugBank: Zafirlukast (DB00549)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral zafirlukast (Z) 20 mg twice daily
Trial: 3615688
Drug: Imipramine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (mean dose = 233 mg/day)
Trial: 29369537
Drug: Patiromer 16.8
RxNorm normalized name: patiromer 16.8 GM Powder for Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patiromer 16.8 g/day (divided into two doses) with individualized titration
Trial: 24279685
Drug: Control (Cyclosporin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Cyclosporin, mycophenolate and steroids)
Trial: 24373555
Drug: Mixed tocotrienols
RxNorm normalized name: Mixed Tocotrienols 50mg Softgel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed tocotrienols 200 mg twice daily
Trial: 20360491
Drug: Single injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection subcutaneous digital nerve block (SDNB)
Trial: 20360491
Drug: Traditional (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional (two injection) digital nerve block (TDNB)
Trial: 16491747
Drug: Medicine group
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medicine group (Yiqi Jianpi Oral Liquid, twice each day, for 4 weeks)
Trial: 12834665
Drug: Generic timolol
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Generic timolol XE gel-forming solution
Trial: 12834665
Drug: Pilopine gel
RxNorm normalized name: pilocarpine hydrochloride Ophthalmic Gel [Pilopine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilopine gel
Trial: 9008994
Drug: Midlaser therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midlaser therapy with TMJ/occlusal stabilization
Trial: 28592888
Drug: GRAALL treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GRAALL treatment
Trial: 29106437
Drug: 120 units
RxNorm normalized name: cholecalciferol 120 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 units of abobotulinumtoxinA injected in 5 equal aliquots (24 units each) into 5 injection sites in the glabellar complex
Trial: 20553679
Drug: Low-dose leuprolide
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose leuprolide acetate administered subcutaneously at 4- to 5-day intervals up to 1 year
Trial: 20553679
Drug: Single GnRH-agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single GnRH-agonist injection
Trial: 20553679
Drug: Repeated dosing
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated dosing of GnRH-agonist
Trial: 18295023
Drug: Early combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early combined immunosuppression (infliximab 5 mg/kg at weeks 0, 2, and 6, plus azathioprine)
Trial: 26671202
Drug: Automated fractional
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated fractional skin microneedling (0.5 mm depth) followed by application of topical anesthetic cream (Lidocaine 2.5% + Prilocaine 2.5%)
Trial: 18061271
Drug: Topical anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anesthesia alone
Trial: 20346190
Drug: Fibre-supplemented diet
RxNorm normalized name: Fiore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibre-supplemented diet (14 g/l)
Trial: 15213095
Drug: ICE consolidation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICE consolidation therapy (idarubicin 9 mg/m2 x 3; cytarabine 3 g/m2 twice a day on days 1, 3, 5, 7; etoposide 75 mg/m2 x 7)
Trial: 15213095
Drug: IcE consolidation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IcE consolidation therapy (cytarabine 100 mg/m2 daily x 5, idarubicin x 2, etoposide x 5)
Trial: 1827621
Drug: Methylprednisolone (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (0.6 mg/kg total body weight)
Trial: 6119098
Drug: Quazepam 7.5
RxNorm normalized name: quazepam 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quazepam 7.5 mg
Trial: 6119098
Drug: Quazepam 45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quazepam 45 mg
Trial: 6119098
Drug: Quazepam 0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quazepam 0 mg (placebo)
Trial: 31004339
Drug: Autologous muscle-derived
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous muscle-derived cell (MDC) injection
Trial: 26113648
Drug: 14 g
RxNorm normalized name: GINGER 14 g in 100 TOPICAL PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 g of free essential amino acids (EAA) with high leucine levels
Trial: 23261050
Drug: Self-administration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administration of intranasal live attenuated influenza vaccine (SA-LAIV)
Trial: 23261050
Drug: Health care
RxNorm normalized name: Health Care Lancing Device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health care provider administration of intranasal live attenuated influenza vaccine (HCP-LAIV)
Trial: 18802735
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no neoadjuvant therapy)
Trial: 14646682
Drug: Comparison among
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison among treatment groups
Trial: 1280910
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for lateral epicondylitis
Trial: 30151895
Drug: 0.4 ml
RxNorm normalized name: ethanol 0.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 ml of daily olive oil supplementation per rooster (Group 3)
Trial: 30151895
Drug: 0.2 ml
RxNorm normalized name: isopropyl alcohol 0.2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 ml of daily olive oil supplementation per rooster (Group 2)
Trial: 24739333
Drug: Ghrelin (5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ghrelin (5.0 μg/kg)
Trial: 10616997
Drug: Trimetazidine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (60 mg orally per day, started 3 weeks preoperatively)
Trial: 7488409
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (MPA) 1000 mg daily
Trial: 7488409
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (MPA) 500 mg daily
Trial: 2301519
Drug: Mifepristone (RU‐486)
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mifepristone (RU‐486) 50 mg
Trial: 2301519
Drug: Mifepristone (RU‐486)
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mifepristone (RU‐486) 100 mg
Trial: 2301519
Drug: Mifepristone (RU‐486)
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mifepristone (RU‐486) 200 mg
Trial: 2301519
Drug: Mifepristone (RU‐486)
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mifepristone (RU‐486) 400 mg
Trial: 2301519
Drug: Mifepristone (RU‐486)
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mifepristone (RU‐486) 600 mg
Trial: 2301519
Drug: Mifepristone (RU‐486)
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mifepristone (RU‐486) 0 mg
Trial: 31365099
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 supplementation (30 μg/d)
Trial: 25877442
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg Lidose hard capsule
Trial: 25877442
Drug: 145 mg
RxNorm normalized name: levodopa 145 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 145 mg nanoparticle tablet
Trial: 17223857
Drug: Brivaracetam (10-1400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brivaracetam (10-1400 mg)
Trial: 17223857
Drug: Brivaracetam (1400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brivaracetam (1400 mg)
Trial: 17223857
Drug: Brivaracetam (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brivaracetam (150 mg)
Trial: 17223857
Drug: Brivaracetam (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brivaracetam (600 mg)
Trial: 17223857
Drug: Brivaracetam (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brivaracetam (150 mg) with high-fat meal
Trial: 14707412
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g L-arginine infusion
Trial: 11730275
Drug: Resting period
RxNorm normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Resting period (R) after a protein meal (1.2 g/kg b.w. of protein)
Trial: 11730275
Drug: Behavioural stress
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioural stress period (S) after a protein meal (1.2 g/kg b.w. of protein)
Trial: 1827271
Drug: Metoclopramide 4
RxNorm normalized name: metoclopramide 4 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 4 mg/kg as a single intravenous dose (regimen A)
Trial: 1827271
Drug: Metoclopramide 3
RxNorm normalized name: metoclopramide 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 3 mg/kg in two doses (regimen B)
Trial: 1827271
Drug: Regimen A
RxNorm normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen A (single dose)
Trial: 1827271
Drug: Regimen B
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen B (divided dose)
Trial: 21084429
Drug: Crossover groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crossover groups (GD→C or CD→G)
Trial: 16899425
Drug: Fumaric acid
RxNorm normalized name: Fumaric Acid
DrugBank: Fumaric acid (DB01677)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fumaric acid esters (FAE's, Fumaderm) at a maximum dose of 120 mg dimethylfumarate per day for six months
Trial: 16186995
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition supplemented with 0.57 g/kg glutamine‐dipeptide
Trial: 18620511
Drug: Chloroquine treatment
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine treatment (600 mg at day 1, 600 mg at days 2 and 3, 300 mg at days 4 and 5)
Trial: 16094063
Drug: 1 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml/kg 0.125% bupivacaine with 1 microg/kg clonidine
Trial: 16094063
Drug: 1 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml/kg 0.125% bupivacaine (controls)
Trial: 12165122
Drug: Combined phototherapy
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined phototherapy and low-intensity laser therapy (LILT) with parameters: 532 mW; 5 kHz; 12 J/cm² for 4 weeks
Trial: 12165122
Drug: Placebo (sham
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (sham treatments)
Trial: 9933035
Drug: TUMT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TUMT plus tamsulosin (0.4 mg daily)
Trial: 7772590
Drug: Orthoptic exercises/treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orthoptic exercises/treatment
Trial: 2177647
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine oestrogens 1.25 mg daily + dydrogesterone 20 mg daily for 12 days during months 2, 3, and 4, then 10 mg daily for the same duration in months 5, 6, and 7
Trial: 2177647
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine oestrogens 1.25 mg daily + dydrogesterone (two doses in reverse sequence)
Trial: 2177647
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine oestrogens 1.25 mg daily
Trial: 6255535
Drug: Griseofulvin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Griseofulvin (250 mg daily)
Trial: 16570816
Drug: Intranasal Budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intranasal Budesonide (256 microg once daily intranasally for 8 weeks)
Trial: 12808485
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of atorvastatin every other day
Trial: 8632574
Drug: Luteinizing hormone‐releasing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luteinizing hormone‐releasing hormone agonist therapy for 12 weeks
Trial: 1999793
Drug: PCA morphine
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCA morphine with low-dose continuous morphine infusion (PCA-plus)
Trial: 1999793
Drug: Intramuscularly administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscularly administered morphine
Trial: 21642642
Drug: 0.7 ml
RxNorm normalized name: ethanol 0.7 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.7 ml kg(‐1) ropivacaine
Trial: 21642642
Drug: 1.0 ml
RxNorm normalized name: digoxin 0.25 mg in 1.0 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 ml kg(‐1) ropivacaine
Trial: 21642642
Drug: 1.3 ml
RxNorm normalized name: 1.3 ML Abilify 7.5 MG/ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.3 ml kg(‐1) ropivacaine
Trial: 16934729
Drug: Deep transverse
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep transverse friction myotherapy (after two treatment sessions)
Trial: 11737959
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A plus Fe supplementation (4800 retinol equivalent vitamin A, 120 mg Fe, and 500 microg folic acid)
Trial: 11737959
Drug: Fe supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fe supplementation alone (120 mg Fe and 500 microg folic acid)
Trial: 9881325
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg 17 beta‐oestradiol daily on days 1‐28, combined with either 5 or 10 mg dydrogesterone on days 15‐28 for 12 months (13 cycles of 28 days)
Trial: 7867285
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with plasma exchange and immune globulins
Trial: 2522007
Drug: Nicardipine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine (60 mg daily, for two months)
Trial: 29262795
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) 900 mg once daily for six months
Trial: 29262795
Drug: Placebo (similar-looking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (similar-looking placebo tablets)
Trial: 21956102
Drug: No hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No hormone replacement therapy (no HRT)
Trial: 18471588
Drug: Hand-held computer
RxNorm normalized name: PRECISION Q-I-D SENSOR,HAND HELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hand-held computer (PDA) intervention with daily feedback and goal-setting
Trial: 7672138
Drug: Octreotide (long‐acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (long‐acting somatostatin analogue) administered SC for 6 weeks
Trial: 7412158
Drug: Methazolamide (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methazolamide (oral doses)